secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084207
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne posts FY2025 net loss $446M; z-rostudirsen BLA submission on track for Q2 2026
--------------------------------------------------------------------------------

- Net loss $446.2M ($3.47/share) for FY2025 vs $317.4M ($3.37/share) in FY2024; R&D expense $398.3M.
- Cash $1.1B at Dec 31, 2025; expected runway into Q1 2028.
- Z-rostudirsen in DMD met primary endpoint: dystrophin 5.46% of normal (p<0.0001); BLA submission planned Q2 2026.
- Z-basivarsen in DM1: enrollment completion of registrational cohort expected Q2 2026; topline data Q1 2027.
- Advancing four DMD exon-skipping candidates (exons 53, 45, 44, 55) into IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/0001193125-26-084207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer